生物标志物
医学
液体活检
乳腺癌
微小残留病
肿瘤科
活检
阶段(地层学)
机会之窗
疾病
癌症
内科学
疾病监测
计算机科学
古生物学
生物化学
化学
实时计算
白血病
生物
作者
Kerstin Pfister,Henning Schäffler,Sophia Huesmann,Sabine Heublein,Tatjana Braun,Stefan Lukac,Kristina Veselinovic,Franziska Mergel,Thomas W.P. Friedl,Brigitte Rack,Wolfgang Janni,Angelina Fink
摘要
Background: Current breast cancer (BC) surveillance is limited to the detection of local, locoregional or contralateral recurrence. This is based on two outdated studies from the 1990s and ignores current evidence on liquid biopsies, particularly circulating tumor DNA (ctDNA). Summary: ctDNA has been shown to be a reliable prognostic biomarker in early BC surveillance. It can be detected using a tumor-informed or a tumor-agnostic approach. However, conclusive evidence for a survival benefit from ctDNA-guided follow-up, as needed for a paradigm shift in BC surveillance, is still lacking. According to current studies, the lead time, i.e. the time from biomarker detection to clinically overt relapse, can be up to several months. This stage of MRD (minimal or molecular residual disease) offers a new therapeutic window, and, currently, several studies are evaluating the efficacy of treatments initiated within this therapeutic window, based on a positive biomarker finding. Liquid biopsy might also open up the possibility of de-escalating therapy in patients with a negative biomarker result.
科研通智能强力驱动
Strongly Powered by AbleSci AI